Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.8750.

Several research analysts have recently commented on XNCR shares. Royal Bank Of Canada increased their price target on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. JPMorgan Chase & Co. decreased their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Finally, Truist Financial initiated coverage on Xencor in a research note on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective on the stock.

Xencor Price Performance

XNCR opened at $11.62 on Friday. The company has a market capitalization of $829.78 million, a PE ratio of -6.56 and a beta of 0.98. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The business has a 50-day moving average of $14.19 and a 200-day moving average of $12.48.

Insider Buying and Selling

In other Xencor news, VP John R. Desjarlais sold 73,367 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares of the company’s stock, valued at $3,718,943.28. The trade was a 23.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the sale, the chief executive officer owned 466,635 shares of the company’s stock, valued at $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.76% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new stake in shares of Xencor in the first quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after purchasing an additional 344,088 shares during the period. Aberdeen Group plc boosted its holdings in Xencor by 48.2% in the 2nd quarter. Aberdeen Group plc now owns 558,810 shares of the biopharmaceutical company’s stock valued at $4,392,000 after purchasing an additional 181,698 shares during the period. Finally, Inspire Investing LLC grew its position in Xencor by 51.6% in the 2nd quarter. Inspire Investing LLC now owns 49,111 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 16,709 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.